Stryker Co. (NYSE:SYK) Receives $393.65 Consensus Target Price from Analysts

Stryker Co. (NYSE:SYK) has earned an average rating of “Moderate Buy” from the twenty ratings firms that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $393.65.

A number of brokerages recently issued reports on SYK. Piper Sandler reiterated an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Evercore ISI lifted their target price on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Stifel Nicolaus decreased their price target on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Citigroup lifted their price objective on Stryker from $406.00 to $411.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, UBS Group raised their target price on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th.

Insiders Place Their Bets

In related news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,381 shares of company stock worth $24,825,275. Insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SYK. Centennial Bank AR raised its holdings in shares of Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the last quarter. Darwin Wealth Management LLC bought a new stake in Stryker during the 3rd quarter worth about $36,000. Central Pacific Bank Trust Division acquired a new position in shares of Stryker during the 1st quarter worth about $39,000. Hara Capital LLC bought a new position in shares of Stryker in the 3rd quarter valued at about $42,000. Finally, HBW Advisory Services LLC acquired a new stake in shares of Stryker in the third quarter valued at about $42,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.8 %

SYK opened at $378.86 on Friday. Stryker has a fifty-two week low of $276.60 and a fifty-two week high of $381.54. The company has a market capitalization of $144.43 billion, a P/E ratio of 40.30, a P/E/G ratio of 2.83 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm’s fifty day moving average price is $361.46 and its two-hundred day moving average price is $345.77.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.46 earnings per share. On average, analysts anticipate that Stryker will post 12.06 EPS for the current year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.